CanSino Biologics Inc. is an innovative biopharmaceutical company dedicated to exploring best solutions to the prevention of diseases through cutting edge research & development, advanced manufacturing and commercialization of innovative vaccine products for human use worldwide.
Since its establishment in Tianjin, China in 2009, CanSinoBIO has experienced tremendous growth with now more than 1,000 employees, two approved vaccine for Ebola virus disease (Ad5-EBOV) and COVID-19 disease (Ad5-nCoV) and 16 vaccine candidates in the product pipeline. CanSinoBIO has been listed on the Main Board of Hong Kong Exchange and Clearing Limited (HKEx) in March 2019. A year later, CanSinoBIO has successfully listed on the Sci-Tech Innovation Board (STAR Market) of the Shanghai Stock Exchange, making it the first "A+H" dual listing vaccine company. CanSinoBIO is focusing on continually expanding manufacturing capacity for its current vaccine candidates and further enhancing the competitiveness and the scope of its portfolio by promoting the R&D of new vaccine candidates.
Leveraging broad experiences of our accomplished team of scientists and business leaders who had previously held technical and senior management positions at many of the leading pharmaceutical companies in the world, including Sanofi Pasteur, Astra Zeneca, Wyeth (now Pfizer) and CNBG (China), CanSinoBIO has developed four key platform technologies, including adenovirus-based viral vector vaccine, conjugation, protein structure design and recombination as well as vaccine formulation technologies.
In addition, the company has in-licensed a number of new technologies and intellectual properties through collaborations with international research organizations and biotechnology companies. CanSinoBIO collaborates through partnerships with world-class academic centers or start-up companies that develop innovative technologies, to prepare the portfolio of the next decades and ensure sustainable growth of the company.
CanSinoBIO is currently developing 16 vaccine candidates for 13 infectious disease areas, preventing meningitis, pneumonia, tuberculosis, COVID-19, Ebola virus disease, pertussis, diphtheria, tetanus, shingles etc. Among these, Ad5-EBOV, the globally innovative Ebola virus disease vaccine, has received NDA (New Drug Application) approval in China in October 2017. The NDA applications of two meningococcal conjugate vaccines are under NMPA review. Moreover, Ad5-nCoV, the investigational vaccine against COVID-19 has been approved to enter into phase I clinical trial. At present, CanSinoBIO has seven vaccine candidates in the clinical trial stage or clinical trial application stage. There are also six pre-clinical vaccine candidates under development, including one combination vaccine candidate.
CanSinoBIO currently has a Research and Development Center with a floor space of approximately 120,000 square-feet as well as a 380,000 square-feet commercial manufacturing campus, which is designed, qualified and operated according to international cGMP standards (FDA, EU, WHO and China). The GMP pilot plants located in the R&D center have passed EU QPs’ audits. The annual bulk production capacity of the current facilities can reach approximately 70 million to 80 million doses, which will be capable of supporting our commercialization plans for our near-commercial vaccine candidates.
Vaccination is an essential part of effective disease control and prevention. CanSinoBIO is committed to make innovative and high quality vaccines accessible to people all over the world thus empower people to pursue healthy and better life.
| Full name | CanSino Biologics Inc. |
|---|---|
| Abbreviations | CanSinoBIO |
| Code | 688185 |
| Founded | 2009-01-13 |
| Listing | 2020-08-13 |
| Domicile | Tianjiin |
| Website | www.cansinotech.com |
| ir@cansinotech.com | |
| STAR Theme | Biomedicine |
| CSRC Sector | Scientific research and technical service |
| Has weighted voting rights structure? | No |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Earnings Per Share | -1.72 | -0.76 | -0.87 |
| R&D expenditure as a % of operating revenue | 1721.49% | 6645.64% | 4032.15% |
| Operating Revenue | 24,890,414.09 | 2,283,391.88 | 2,811,896.60 |
| Net Income | -396,638,192.10 | -156,781,479.69 | -138,271,720.58 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Revenue | 24.89 | 2.28 | 2.81 |
| Operating Costs | 14.34 | 0.15 | 0.27 |
| Operating Income | -397.82 | -162.07 | -138.36 |
| Pretax Income | -396.64 | -156.78 | -138.27 |
| Income Tax | - | - | - |
| Net Income | -396.64 | -156.78 | -138.27 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 5,420.55 | 794.25 | 220.58 |
| Non-current Assets-Total | 1,327.53 | 990.25 | 575.28 |
| Total Assets | 6,748.08 | 1,784.50 | 795.87 |
| Liabilities | |||
| Current Liabilities-Total | 409.47 | 116.43 | 105.14 |
| Non-current Liabilities-Total | 267.75 | 197.55 | 188.40 |
| Total Liabilities | 677.22 | 313.98 | 293.53 |
| Stockholder's Equity | |||
| Share Capital | 6,835.55 | 1,838.57 | 713.61 |
| Retained Profits | -764.69 | -368.05 | -211.27 |
| Total Owners' Equity | 6,070.86 | 1,470.52 | 502.33 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Net Cash Flows-Operating | -349.93 | -154.25 | -123.64 |
| Net Cash Flows-Investing | -319.69 | -813.70 | 117.63 |
| Net Cash Flows-Financing | 4,941.04 | 1,090.82 | 45.05 |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| HKSCC NOMINEES LIMITED | 98.07 | 39.63% |
| Xuefeng YU | 17.87 | 7.22% |
| Tao ZHU | 17.87 | 7.22% |
| Dongxu QIU | 17.11 | 6.92% |
| Helen Huihua MAO | 16.33 | 6.60% |
| QM29 LIMITED | 11.28 | 4.56% |
| LAV Spring (Hong Kong) Co., Limited | 10.39 | 4.20% |
| Future Industry Investment Fund (Limited Partnership) | 8.86 | 3.58% |
| LAV Bio III Investment (Hong Kong) Co., Limited | 4.92 | 1.99% |
| Shanghai Li’an Venture Capital Investment Center (Limited Partnership) | 4.60 | 1.86% |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.